BioPharma Resources

Drug Trial Radar · NCT04501120

Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML

A Phase Ib Study of the Safety, Pharmacokinetic of Lisaftoclax (APG-2575) Single Agent and in Combination With Homoharringtonine or Azacitidine in Patients With Relapsed/Refractory AML

Last checked: Nov 19, 2026Latest source record: Apr 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

682

Planned (sponsor's estimate)

Start

Sep 28, 2020

Primary completion

Sep 2028

Study completion Sep 2029

Sponsor

Lead sponsor
Ascentage Pharma Group Inc.Industry
Sponsor type
Industry
Collaborators
Suzhou Yasheng Pharmaceutical Co., Ltd.
First posted
Aug 6, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety, pharmacokinetic profile of Lisaftoclax (APG-2575) single agent and in combination with HHT/AZA in patients with relapsed/refractory AML and related myeloid malignancies.

Conditions

  • Relapsed/Refractory Acute Myeloid Leukaemia
  • Myeloid Malignancy

Interventions

  • Lisaftoclax (APG-2575)Drug

    Lisaftoclax (APG-2575) orally once daily, every 28 days as a cycle.

  • Reduced-dose HHTDrug

    1mg IV QD on Days 1-14 (28-day cycle).

  • standard-dose HHTDrug

    2mg/m\^2 IV QD on Days 1-7 (28-day cycle).

  • AzacitidineDrug

    75 mg/m\^2 SC or Iv gtt QD on Days 1- 7 (28-day cycle).

  • Lisaftoclax (APG-2575)Drug

    Lisaftoclax (APG-2575) orally once daily for 14 days, every 28 days as a cycle.

  • olverembatinibDrug

    orally, with meals, QOD, every 28 days as a cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Limiting Toxicities (DLT)Time frame: 28 days
  2. Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose(RP2D)Time frame: 28 days

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Chongqing University Cancer Hospital

    Chongqing, Chongqing Municipality, China · Not yet recruiting

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guandong, China · Recruiting

  • Guangdong Provincial People's Hospital

    Guangzhou, Guangdong, China · Recruiting

  • Henan Tumor Hospital

    Zhengzhou, Henan, China · Recruiting

  • Union Hospital medical college Huazhong University of Science and Technology

    Wuhan, Hubei, China · Recruiting

  • Zhongnan Hospital of Hunan university

    Wuhan, Hubei, China · Recruiting

  • Xiangya Hospital Central South University

    Changsha, Hunan, China · Recruiting

  • The First affiliated hospital of Soochow University

    Suzhou, Jiangsu, China · Recruiting

  • Shanghai The Sixth People' s Hospital

    Shanghai, Shanghai Municipality, China · Not yet recruiting

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, China · Recruiting

  • the First Affiliated Hospital, College of Medicine, Zhejiang University

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.